Dopamine Receptor Modulation in Co-Occurring Disorders: Potential of Cariprazine and D3 Receptor Activity

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Substance use disorders (SUDs) often co-occur with serious mental illness (SMI), leading to undertreatment due to limited pharmacologic options.
• Dopamine receptor-modulating agents (DRMAs), including antipsychotics, are explored for their potential to impact craving, reward processing, and relapse in SUDs.

Purpose of the Study:

• To review the evidence for dopamine receptor modulation in SUD treatment, focusing on second-generation antipsychotics (SGAs) and the D3-preferring partial agonist cariprazine.
• To examine the role of dopamine D2 versus D3 receptor activity in SUDs and the emerging data on cariprazine.

Main Methods:

• A narrative review of preclinical, clinical, and observational studies.
• Focus on dopamine receptor antagonists and partial agonists in SUD populations, including those with co-occurring SMI.
• Analysis of pharmacologic mechanisms and emerging evidence for cariprazine.

Main Results:

• First-generation antipsychotics showed limited benefit for SUDs.
• SGAs exhibited heterogeneous effects, influenced by receptor profiles.
• Increasing evidence implicates the dopamine D3 receptor in SUD-related motivation and reward.
• Cariprazine demonstrated potential benefits in preclinical and observational studies for reducing substance use, craving, and relapse, particularly for stimulant and cannabis use disorders.

Conclusions:

• Dopamine receptor modulation, especially D3-targeting, is a promising emerging strategy for SUD treatment, particularly in dual diagnosis populations.
• Cariprazine's unique D3 receptor profile makes it a compelling candidate for further research.
• Rigorous randomized controlled trials are essential to confirm cariprazine's efficacy and define its role in integrated treatment models.